| [1] Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:393- 403.[2] Dominici M, Le Blanc K, Mueller I,et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.[3] Zuk PA,Zhu M,Ashjian P, et aI.Human adipose tissue is a source of multipotent stem cells．Mol boiI celI.2002;13: 4279-4295.[4] 张美,吕国枫.骨髓间充质干细胞向软骨的诱导分化[J].中国组织工程研究与临床康复,2010,14(45):8483-8486.[5] Worster AA,Brower-Toland BD,Fortier LA,et al.Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor-beta 1 in monolayer and insulin-like growth factor-1 in a three-dimensional matrix. J Orthop Res.2001;19(4):738-749.[6] 邓进,彭吾训,王蕾,等.骨髓间充质干细胞二维培养条件下向软骨细胞诱导分化的实验研究[J].中国现代医学杂志,2008,18(16): 2340-2343.[7] Pittenger MF, Mackay AM, Beck SC, et al.Multilineage potential of adult human mesenchymal stem cells.Science. 1999;284:143-147.[8] 徐道华,周晨慧,刘钰瑜,等.大鼠骨髓间充质干细胞分化成脂肪细胞的定向诱导[J].中国组织工程研究与临床康复,2009,13(1): 125-128.[9] Xu M, Wani M, Dai YS,et al. Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes. Circulation. 2004;110:2658- 2665.[10] Deans RJ,Moseley AB.Mesenchymal stem cells:Biology and potential clinical uses.Exp Hematol.2000;28:875-884.[11] Klyushnenkova E, Mosca JD, Zemetkina V,et al.T cell responses to allogeneic human mesenchymal stem cells:immunogenicity,tolerance and suppression.Biomed Sci. 2005,12:47-57.[12] Di Nicola M,Carlo-Stella C,Magui M,et al.Human bone marrow strom al cells suppress T-lym phocyte proliferation induced by cellularor nonspecific mitogenic stimuli.Blood. 2002; 99:3838-3843.[13] Basara N,Kiehl MG,Fauser AA.New therapeutic modalities in the treatment of graft-versus-host disease.Crit Rev Oncol Hematol.2001;38(2):129-138.[14] Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-736.[15] Spaggiari GM,Capobianco S,Becchetti S,et al.Mesenchymal stem cell-natural killer cell interactions;evidence that activated NK cells are capable of killing MSCs,whereas MSCs can inhibit IL-2-induced NK-cell Proliferation.Blood. 2006;107;1484-1490.[16] Raffaghello L, Bianchi G, Bertolotto M, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26:151-162.[17] Bingisser RM, Tilbrook PA, Holt PG,et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol. 1998; 160 (12): 5729-5734.[18] Meisel R, Zibert A, Laryea M, et al.Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood.2004;103:4619-4621.[19] Spaggiari GM,Abdelrazik H,Becchetti F,et al.MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs:central role of MSC-derived prostaglandin E2.Blood.2009;113:6576-6583.[20] Wehner R,Wehrum D,Bornhauser M,et al.Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells.Haematologica.2009;94:1151-1156.[21] Németh K, Leelahavanichkul A, Yuen PS,et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med.2009;15:42- 49.[22] Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymalstem cells. Blood. 2007;109(1):228-234.[23] Bartholomew A,Sturgeon C,Siatskas M,et al.Mesenehymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol.2002; 30(1): 42-48.[24] Halkos ME, Zhao ZQ, Kerendi F, et al. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol. 2008;103:525-536.[25] Quevedo HC, Hatzistergos KE, Oskouei BN,et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA. 2009;106:14022-14027.[26] Schuleri KH, Feigenbaum GS, Centola M,et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J. 2009;30: 2722-2732.[27] 程芮,王士雯,张友荣,等.3种不同途径移植自体骨髓间充质干细胞治疗急性心肌梗死效果比较[J].中华实验外科杂志,2005, 22(12): 1504-1506.[28] Luo Z,Diaco M,Murohara T,et al.Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury．Ann Thorac Surg.1997;64:993-998.[29] Tang YL, Zhao Q, Qin X, et al.Paracrine Action Enhan ces the Efects of Autologous Mesenchymal Stem Cel1 Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction．Ann Thorac Surg.2005;80 229-237.[30] Tang YL,Zhao Q,Zhang YC,et al.Autologous mesenchymal stem cel1 trailsplantation induce VEGF and neovascularlz. ation in ischemic myocardium. Regul Pept.2004;117:3-10.[31] Xu MF,Uemura R,Dai Y,et al.In vitro and in vivo eFfects of bone marrow stem cells on cardiac structure and function．J Mol Cell Cardiol.2007;42(2):441-448.[32] Bhakta S,Hung P,Koc O．The surface adhesion molecule CXCR4stimulates mesenehymal stem cell migration to strommal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation.Cardiovasc Revasc Med. 2006;7(1):19-24.[33] Sürder D, Schwitter J, Moccetti T,et al.Cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISSAMI).Am Heart J. 2010;160:58-64.[34] Hare JM, Traverse JH, Henry TD,et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54: 2277-2286.[35] Trachtenberg B, Velazquez DL, Williams AR,et al.Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: a randomized, double-blind,placebo-controlled study of safety and efficacy. Am Heart J. 2011;161:487- 493. |
